GSK chief predicts slower M&A pace

GlaxoSmithKline's M&A pace is likely to slow down, CEO Andrew Witty tells Reuters. The supply of transactions that will deliver GSK's required ROI is drying up, Witty says, after a year of brisk-paced bolt-on acquisitions. Says Witty: "I think we are in a period where they are more difficult to get at the levels we would be prepared to pay." Report